Core Viewpoint - A class action has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the Phase III Orbit and Cosmic Studies for setrusumab, which tested its efficacy in treating Osteogenesis Imperfecta [1][2]. Group 1: Allegations and Misleading Information - The complaint alleges that Ultragenyx provided overly positive statements about setrusumab's expected results, claiming it would decrease the annualized fracture rate in patients with Osteogenesis Imperfecta [2]. - Defendants are accused of concealing material adverse facts about setrusumab's potential and the risks associated with the study protocols, specifically that while setrusumab increases bone density, it does not correlate with a decrease in fracture rates [3]. Group 2: Study Results and Stock Impact - On December 29, 2025, Ultragenyx announced that the Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonates [4]. - Following this announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in one day [4]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Ultragenyx and can contact Robbins LLP if they wish to serve as lead plaintiff [5]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [5].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly making false and misleading statements regarding its drug candidate's performance during a Phase III trial [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from August 3, 2023, to December 26, 2025, with a deadline for lead plaintiff appointments set for April 6, 2026 [2]. - The complaint alleges that Ultragenyx created falsely optimistic beliefs about its drug candidate's performance, failing to achieve statistically significant endpoints despite positive communications [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2][3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged misleading statements regarding the efficacy of setrusumab, impacting investors who purchased stock between August 3, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made false or misleading statements about setrusumab's potential, specifically that while it increases bone density, it does not correlate with a decrease in fracture rates, contrary to management's claims [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking highly in the industry since 2013 [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged misleading statements regarding the efficacy of setrusumab, impacting investors who purchased stock between August 3, 2023, and December 26, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made false statements about setrusumab's potential, specifically that while it increases bone density, this does not correlate with a decrease in fracture rates, contrary to management's claims [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to allegations of violations of federal securities laws related to misleading statements about the effects of setrusumab on patients with Osteogenesis Imperfecta [4]. Group 1: Legal Investigation - The law firm is encouraging Ultragenyx investors who suffered losses exceeding $50,000 to contact them for discussing legal options [1]. - A federal securities class action has been filed against Ultragenyx, with a deadline of April 6, 2026, for investors to seek the role of lead plaintiff [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives created a false impression regarding the reliability of information on setrusumab's effects, while downplaying the risks associated with the Phase III Orbit study [4]. - It is claimed that Ultragenyx's optimism regarding the study's results was misplaced, as the data was based on Phase II results without a placebo control group, raising concerns about the validity of the findings [4]. Group 3: Participation and Whistleblower Information - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [5]. - The firm is also encouraging individuals with information regarding Ultragenyx's conduct, including whistleblowers and former employees, to come forward [6].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. and certain officers for alleged violations of federal securities laws during the Class Period from August 3, 2023, to December 26, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Ultragenyx securities during the specified Class Period [2]. - The Complaint alleges that the defendants made false and misleading statements regarding the effects of setrusumab on patients with Osteogenesis Imperfecta and downplayed the risks associated with the Phase III Orbit study [3]. - It is claimed that Ultragenyx's optimism regarding the Phase III study results was unfounded, as the Phase II results lacked a placebo control group, raising concerns about the validity of the reported reduction in annualized fracture rate [3]. Group 2: Next Steps for Investors - Investors affected by the situation have until April 6, 2026, to request to be appointed as lead plaintiff in the class action [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in similar cases [6].

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab during clinical trials [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Bailey v. Ultragenyx Pharmaceutical Inc. and covers purchasers of Ultragenyx common stock from August 3, 2023, to December 26, 2025 [1]. - Investors have until April 6, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Ultragenyx misrepresented the reliability of information regarding the effects of setrusumab on Osteogenesis Imperfecta patients and downplayed the risks associated with the Phase III Orbit study [3]. Group 2: Study Results and Stock Impact - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [4]. - On December 29, 2025, the company announced that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, resulting in a further stock price decline of more than 42% [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Ultragenyx stock during the class period to seek lead plaintiff status, representing the interests of the class [6]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [7].

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is recognized as one of the best revenue growth stocks, with a focus on developing therapies for rare genetic diseases, particularly through its resubmission of the Biologics License Application for UX111 AAV9 gene therapy targeting Sanfilippo syndrome type A [1][3]. Group 1: Company Developments - The company resubmitted its Biologics License Application (BLA) to the U.S. FDA on January 30, seeking accelerated approval for UX111 AAV9 gene therapy [1]. - The resubmitted BLA addresses previous concerns from the FDA, with an anticipated review period of up to six months, expected to conclude in the third quarter [3]. - If approved, UX111 will be the first therapy available for Sanfilippo syndrome type A [3]. Group 2: Analyst Ratings and Market Position - Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ultragenyx Pharmaceutical with a price target of $50 [3]. - In the past month, Leerink Partners also issued a Buy rating, while Wedbush reiterated a Hold rating on the stock [3]. - The company’s product portfolio includes therapies such as Crysvita, Mepsevii, Dojolvi, and Evkeeza, emphasizing its commitment to rare and ultra-rare genetic diseases [3].

Core Viewpoint - ClaimsFiler is reminding investors about the deadline for filing lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. [1] Group 1: Lawsuit Details - The deadline for filing lead plaintiff applications is April 6, 2026 [1] - The class action lawsuit pertains to investors who purchased or acquired shares of Ultragenyx between August 3, 2023, and December 26, 2025 [1] - The lawsuit is currently pending in the United States District Court for the Southern District of New York [1]

Core Insights - Ultragenyx allegedly misled investors regarding the potential success of setrusumab's Phase 3 study in reducing fracture rates [1] Company Summary - The company is facing allegations of misleading investors about the efficacy of setrusumab in its clinical trials [1]